부산대학교 도서관

Bone Morphogenetic Protein 2 (BMP2), a member of the Transforming Growth Factor‐β (TGF‐β) super family of proteins and is instrumental in the repair of fractures. The synthesis of BMP2 involves extensive post‐translational processing and several studies have demonstrated the abysmally low production of rhBMP2 in eukaryotic systems, which may be due to the short half‐life of the bioactive protein. Consequently, production costs of rhBMP2 are quite high, limiting its availability to the general populace. Therefore, there is an urgent need to identify better in‐vitro systems for large scale production of rhBMP2. In the present study, we have carried out a comparative analysis of rhBMP2 production by the conventionally used Chinese Hamster ovarian cells (CHO) and goat mammary epithelial cells (GMEC), upon transfection with appropriate construct. Udder gland cells are highly secretory, and we reasoned that such cells may serve as a better in‐vitro model for large scale production of rhBMP2. Our results indicated that the synthesis and secretion of bioactive rhBMP2 by goat mammary epithelial cells was significantly higher as compared to that by CHO‐K1 cells. Our results provide strong evidence that GMECs may serve as a better alternative to other mammalian cells used for therapeutic protein production. Significance statement: The present study demonstrates the suitability of primary goat mammary epithelial cells as a system for large scale production of therapeutic proteins in‐vitro. The cells of the mammary gland are highly secretory, and we reasoned that such cells may be useful for in‐vitro production of tough‐to‐produce therapeutics like human Bone Morphogenetic protein 2 (BMP2). We demonstrate that GMECs are a better alternative to the conventionally used CHO‐K1 cells for rhBMP‐2 production. Our results provide a strong case for developing and using GMECs as an alternative system for therapeutic protein expression. [ABSTRACT FROM AUTHOR]